CIC bioGUNE awarded US patent for new cancer treatment product

Tuesday, September 16th, 2014

A product created by CIC bioGUNE laboratories, that will enable cancer or neurodegenerative disease fighting drugs to be developed, has recently been awarded a patent by the United States Patent and Trademark Office (USPTO).

This product, called TUBEs (Tandem-repeated Ubiquitin Binding Entities), and also known as “ubiquitin trap”, is a system that captures molecules involved in protein degradation. CIC bioGUNE, the Center for Cooperative Research in Biosciences, began its activity 10 years ago and currently holds 4 patents in exploitation out of 9 patent applications.

The new system protected by the US patent enables identification of potential therapeutic targets for multiple pathologies, such as cancer and certain neurodegenerative diseases, caused by a modification in the intercellular protein destruction process.

It is a molecular tool that captures ubiquitin, a protein whose main function is to mark other proteins for destruction, so as to subsequently identify target proteins of therapeutic interest accurately and efficiently.

Related articles
This may also interest you